March 23, 2020 10:42 AM EDT

BELLUS Health buys IP rights, banishes royalties; AbbVie gets confirmatory data on accelerated AML drug

ENDPOINTS

→ Canada’s BELLUS Health $BLU has bagged the remaining IP rights for its BLU-5937 and related P2X3 antagonists. The deal scraps the tiered royalty payments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BELLUS Health buys IP rights, banishes royalties; AbbVie gets confirmatory data on accelerated AML drug

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

BEL­LUS Health buys IP rights, ban­ish­es roy­al­ties; Ab­b­Vie gets con­fir­ma­to­ry da­ta on ac­cel­er­at­ed AML drug

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

BELLUS Health buys IP rights, banishes royalties; AbbVie gets confirmatory data on accelerated AML drug

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?